Disc Medicine (IRON) Cash from Investing Activities (2020 - 2026)
Disc Medicine (IRON) reported Cash from Investing Activities of $58.3 million for Q1 2026, up 121.39% year-over-year from $26.3 million in Q1 2025, and up 126.16% quarter-over-quarter from -$222.9 million in Q4 2025.
Disc Medicine (IRON) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Disc Medicine (IRON) has 7 years of Cash from Investing Activities data on file, last reported at $58.3 million in Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at $58.3 million, up 121.39% year-over-year; the trailing twelve-month figure through Mar 2026 was -$63.4 million (up 88.78% YoY), and the FY2025 annual result was -$394.3 million, down 34.88% from the prior year.
- Cash from Investing Activities rose to $58.3 million in Q1 2026 per IRON's latest filing, from -$222.9 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $58.3 million in Q1 2026 and troughed at -$272.6 million in Q1 2025.
- A 5-year average of -$37.0 million and a median of -$29000.0 in 2023 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities tumbled 1831141.67% in 2024, then soared 169.68% in 2025.
- A 5-year view of Cash from Investing Activities shows it stood at -$12000.0 in 2022, then soared by 75.0% to -$3000.0 in 2023, then slumped by 47433.33% to -$1.4 million in 2024, then slumped by 15530.65% to -$222.9 million in 2025, then jumped by 126.16% to $58.3 million in 2026.
- Business Quant data shows IRON's Cash from Investing Activities at $58.3 million in Q1 2026, -$222.9 million in Q4 2025, and $49.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 579,519.10 |
| 10 | Disc Medicine | 2.62 Bn | 1.89 Bn | - | 58.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58.31 Mn |
| Mar 31, 2026 | 58.31 Mn |
| Dec 31, 2025 | -222.89 Mn |
| Dec 31, 2025 | -222.89 Mn |
| Sep 30, 2025 | 49.54 Mn |
| Sep 30, 2025 | 49.54 Mn |
| Jun 30, 2025 | 51.69 Mn |
| Jun 30, 2025 | 51.69 Mn |
| Mar 31, 2025 | -272.63 Mn |
| Mar 31, 2025 | -272.63 Mn |
| Dec 31, 2024 | -1.43 Mn |
| Dec 31, 2024 | -1.43 Mn |
| Sep 30, 2024 | -71.09 Mn |
| Sep 30, 2024 | -71.09 Mn |
| Jun 30, 2024 | -219.75 Mn |
| Jun 30, 2024 | -219.75 Mn |
| Mar 31, 2024 | -67,000.00 |
| Mar 31, 2024 | -67,000.00 |
| Dec 31, 2023 | -3,000.00 |
| Dec 31, 2023 | -3,000.00 |